AMCHAM’s Medical Devices Committee held a meeting chaired by the Vice Chairman of AMCHAM, Mr. Chaitanya Sarawate, Chairman – Medical Devices Committee, AMCHAM and President & CEO, GE HealthCare South Asia, on September 26th virtually. The meeting brought together CEOs and senior leaders from leading U.S. MedTech companies. It was decided to chart 3–5 focused priorities for the year ahead, against the backdrop of a rapidly evolving policy and regulatory environment in India and the U.S. Members agreed to focus on a narrowed, high-impact agenda that reflects AMCHAM’s strengths in engaging both the U.S. and Indian governments. The current issues and challenges addressed were: 1. Policy & Regulatory Shifts: GST changes, U.S.-India bilateral treaty agreement (BTA) negotiations, pricing and TMR, 2. Operational Issues with CDSCO: Lengthy approval delays for new products and post-approval changes, lack of clarity on PACs, and overlapping regulations from multiple ministries, and 3. Compliance Burdens: Quality Control Orders, labelling, and multi stakeholder involvement. Proposed priorities for 2025–26 included government procurement and market access, regulatory compliance, ease of doing business, pricing and future policy engagement – monitor trade margin rationalization (TMR), contribute to IP law discussions for MedTech, and shape emerging policy frameworks. The meeting saw active contributions from senior representatives of Bausch & Lomb, Becton Dickinson, Bio-Rad, Boston Scientific, DuPont, Edwards Lifesciences, GE Healthcare, Johnson & Johnson, Lifescan, Medtronic, Ortho Clinical Diagnostics (Quidel Ortho), Stryker, Zimmer, and others, alongside the AMCHAM Secretariat.